Class 4 Medicines Notification: Irbesartan 150 mg and 300 mg film-coated tablets, EL(25)A/02
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.
DMRC reference number
DMRC 34132023
Company name
Jubilant Pharmaceuticals NV
Irbesartan 150 mg film-coated tablets, PL 19156/0089
SNOMED Code
42375311000001101, 1126711000001102, 21123311000001108, 21123511000001102, 29880111000001105, 29880211000001104
| Batch Number | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| IR222002A | 08/2025 | 28 | 5 December 2023 |
| IR222003A | 08/2025 | 28 | 8 January 2024 |
| IR222004A | 09/2025 | 28 | 16 November 2023 |
| IR222006A | 09/2025 | 28 | 5 February 2024 |
| IR222007A | 09/2025 | 28 | 1 March 2024 |
| IR222008A | 09/2025 | 28 | 2 April 2024 |
| IR224001A | 03/2027 | 28 | 5 September 2024 |
| IR224002A | 03/2027 | 28 | 12 September 2024 |
| IR224003A | 03/2027 | 28 | 19 September 2024 |
| IR224004A | 06/2027 | 28 | 20 November 2024 |
Irbesartan 300 mg film-coated tablets, PL 19156/0090
SNOMED Code
42375511000001107,1080311000001103, 21100511000001103, 21100611000001104, 21123811000001104, 21124111000001108, 29880311000001107, 29886711000001109
| Batch Number | Expiry Date | Pack Size | First Distributed |
|---|---|---|---|
| IR322001C | 02/2025 | 28 | 5 December 2023 |
| IR322002C | 02/2025 | 28 | 1 February 2024 |
| IR322003A | 08/2025 | 28 | 16 November 2023 |
| IR324002A | 06/2027 | 28 | 11 November 2024 |
| IR324003A | 06/2027 | 28 | 26 November 2024 |
| IR324004A | 06/2027 | 28 | 6 December 2024 |
Active Pharmaceutical Ingredient: Irbesartan
Brief description of the problem
Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batch listed in the table above include an outdated PIL. These packs contain a PIL which was last revised in September 2015. The latest current approved PIL is dated August 2022.
The out-of-date PIL last revised in September 2015 is missing important updated safety information, please refer to the table in Appendix 1 in the PDF for information regarding updated safety information that is included in the most recent PIL from August 2022. The latest (current) PIL is already available on the MHRA’s website.
Advice for healthcare professionals
Healthcare professionals are advised to review the information contained within this notification and take this into account when prescribing this product. When product from batch included in the table is supplied or dispensed, please ensure that patients are aware of the missing information. As the patients would not find current PIL (dated: Aug 2022) in the packs, please inform the patients that this latest (current) PIL of Irbesartan Jubilant film-coated tablets is already available on the MHRA’s website.
Advice for patients
Patients should continue to take medicines from the impacted batch as prescribed by your healthcare professional. This does not affect the quality of the product. There are updated safety information in the latest patient information leaflet (PIL) which accompanies the medicine. The latest (current: last revised in Aug 2022) PIL is already available on the MHRA’s website.
As per current PIL there is some missing information which is presented below:
What you need to know before you take Irbesartan Jubilant
Warnings and precautions
Talk to your doctor or pharmacist before taking Irbesartan Jubilant if
- if you develop low blood sugar levels (symptoms may include sweating, weakness, hunger, dizziness, trembling, headache, flushing or paleness, numbness, having a fast, pounding heart beat), particularly if you are being treated for diabetes.
You may need to have blood checks if you take:
- repaglinide (medication used for lowering blood sugar levels)
Possible side effects
- Decreased number of red blood cells (anaemia – symptoms may include tiredness, headaches, being short of breath when exercising, dizziness and looking pale), reduced number of platelets, severe allergic reactions (anaphylactic shock) and low blood sugar levels.
Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Further information
For medical information enquiries please contact: safety.uk@lambda-cro.com, Telephone number: 0080089013370
For stock control enquiries please contact: JPUK.Customerservice@jubl.com, Telephone: +4401233 552293
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download document